Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

DFT383 in partecipanti pediatrici con cistinosi nefropatica (CYStem)

15 ottobre 2026 aggiornato da: Novartis Pharmaceuticals

Uno studio di etichetta aperta, multicentrica, fase I/II per valutare la sicurezza, la tollerabilità e l'efficacia di DFT383 nei partecipanti pediatrici con cistinosi nefropatica

An open-label, multi-center, phase I/II study to assess the safety, tolerability and efficacy of DFT383 in pediatric participants with nephropathic cystinosis, followed by a long-term extension phase.

The purpose of this clinical study is to assess safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis. The study consists of a Core Phase and a long-term Extension Phase. DFT383 is a cellular gene therapy.

This study includes an active arm (Cohort 1) of participants treated with study treatment DFT383 and a concurrent reference arm (Cohort 0). Participants in Cohort 0 will not receive study treatment and will only participate in the Core Phase of the study. The study is not randomized and Cohort 0 aims to collect prospective and concurrent data in this rare disease.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This study is an open-label, multi-center, phase I/II study to assess the safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis, followed by a long-term extension phase.

The study includes two Treatment Groups (Cohort 1 and Cohort 0) and consists of a Core Phase and a long-term Extension Phase.

Participants in Cohort 1 will receive DFT383 and participate in both the Core and Extension Phase. Participants in Cohort 0 will not receive study treatment and will participate in the Core Phase only.

The two cohorts will be run in parallel. Investigational sites may participate in one or both cohorts.

Cohort 1 Approximately 15 participants will receive treatment with DFT383 in 3 (sub) cohorts (1A, 1B and 1C) dosed in a staggered approach. The total study duration for a participant in Cohort 1 will be up to 32 months in the core phase and up to 13 years for the long-term extension phase.

Cohort 0 Approximately 15 participants meeting similar inclusion/exclusion criteria and receiving SoC will be enrolled. The Schedule of Activities will be reduced for this Cohort. This cohort 0 is not a direct control but will provide essential context for interpreting the results observed in the participants receiving DFT383. The total study duration for a participant in Cohort 0 will be up to 24 months.

Tipo di studio

Interventistico

Iscrizione (Stimato)

30

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

  • Nome: Novartis Pharmaceuticals

Luoghi di studio

    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85016
        • Reclutamento
        • Phoenix Children's Hospital (Recruiting Cohort 0 and 1)
        • Contatto:
        • Investigatore principale:
          • Shanna White
    • California
      • San Diego, California, Stati Uniti, 92123
        • Reclutamento
        • University of California at San Diego - Rady Children's Hospital (Recruiting Cohort 0 and 1)
        • Contatto:
        • Investigatore principale:
          • Nadine Benador nbenador@health.ucsd.edu
      • Stanford, California, Stati Uniti, 94305
        • Reclutamento
        • Stanford University - Stanford Children's Health (Recruiting Cohort 0 and 1)
        • Investigatore principale:
          • Alice Bertaina
        • Contatto:
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Reclutamento
        • Emory University School of Medicine - Children's Healthcare of Atlanta (recuiting Cohort 0)
        • Investigatore principale:
          • Laurence (Larry) Greenbaum
        • Contatto:
          • Laurence (Larry) Greenbaum
          • Numero di telefono: 404-712-6374
          • Email: lgreen6@emory.edu
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Reclutamento
        • Children's Hospital of Philadelphia (Recruiting Cohort 0)
        • Contatto:
          • Melissa Cadnapaphornchai
          • Numero di telefono: 215-590-2449
        • Investigatore principale:
          • Melissa Cadnapaphornchai
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • Baylor College of Medicine - Texas Children's Hospital (recuiting Cohort 0)
        • Contatto:
        • Investigatore principale:
          • Ewa Elenberg

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 2 anni a 5 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Key Inclusion Criteria:

Participants eligible for inclusion in this study must meet all the following criteria:

  1. Informed consent in writing from parent(s) or legal guardian(s) must be provided
  2. 2 to 5 years of age (including 5 years and 364 days old) at Screening
  3. Weight-for-stature is ≥ the third percentile, and is ≥ 10 kg
  4. Oral cysteamine therapy for at least 6 months
  5. Historic clinical diagnosis of nephropathic cystinosis
  6. Laboratory evidence of of renal fanconi syndrome (RFS)
  7. Relatively preserved kidney function (eGFR ≥ 60mL/min/1.73m2)
  8. Received all age-appropriate vaccinations

Key exclusion Criteria for Cohort 1 and 0

  1. A history of kidney transplantation
  2. A prior or planned bone marrow or stem cell transplantation or prior treatment with gene therapy
  3. History of malignancy
  4. A severe or uncontrolled medical disorder
  5. Major surgery within 90 days

Additional Key exclusion criteria for Cohort 1 - The following exclusion criterion applies to Cohort 1 only as it is related to DFT383 treatment:

1. Indomethacin within 2 weeks prior to Screening

Other protocol-defined inclusion/exclusion criteria may apply.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Cohort 1 (DFT383)

Treatment with DFT383

DFT383 is an autologous hematopoietic stem cell (HSC) gene therapy.

Nessun intervento: Cohort 0 (SoC)

No study treatment, will continue with standard of care (cysteamine).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Core Phase - Incidence of adverse events (Cohort 1)
Lasso di tempo: Up to 32 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

Up to 32 months
Core Phase - Number of participants with hematological reconstitution (Cohort 1)
Lasso di tempo: 42 days post DFT infusion

Hematological reconstitution by Day 42 post-DFT383 infusion

42 days post DFT infusion
Core Phase - Proportion of participants with reversal of renal Fanconi syndrome (RFS)
Lasso di tempo: Up to 32 months

Proportion of participants with reversal of renal Fanconi syndrome (RFS)

Up to 32 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Core Phase - Number of participants independent from cysteamine
Lasso di tempo: up to 24 months

Independence from oral and ophthalmic cysteamine

up to 24 months
Core Phase - Health-related quality of life (HRQOL)
Lasso di tempo: Up to 32 months

Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development

Up to 32 months
Core Phase - Time from infusion to reversal of RFS (Cohort 1)
Lasso di tempo: Up to 24 months

Time from infusion to reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Time from screening to reversal of RFS (Cohort 0)
Lasso di tempo: Up to 24 months

Time from screening to reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Duration of reversal of RFS
Lasso di tempo: Up to 24 months

Duration of reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR)
Lasso di tempo: Up to 27 months

Change from baseline on urine protein to creatinine ratio (UPr/CR)

Up to 27 months
Core Phase - Change from baseline on urine amino acids
Lasso di tempo: Up to 27 months

Change from baseline on urine amino acids

Up to 27 months
Core Phase - Change from baseline on urinary glucose to creatinine ratio
Lasso di tempo: Up to 27 months

Change from baseline on urinary glucose to creatinine ratio

Up to 27 months
Core Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR)
Lasso di tempo: Up to 27 months

Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio

Up to 27 months
Core Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr)
Lasso di tempo: Up to 27 months

Change from baseline on urine retinol-binding protein/creatinine ratio

Up to 27 months
Core Phase - Number of participants with improvement of proximal tubular function
Lasso di tempo: Up to 27 months

Improvement of proximal tubular function as defined by 2-fold change from Baseline of at least 4 out of 5 RFS parameters (urine protein to creatinine ratio, urine amino acids, urinary glucose to creatinine ratio, tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate, urine retinol-binding protein/creatinine ratio). Improvement will also be considered if the change from Baseline is less than 2-fold but the value falls within the definition for normalization.

Up to 27 months
Core Phase - Corneal cystine crystal content
Lasso di tempo: Up to 27 months

Corneal crystal content by anterior segment optical coherence tomography (AS-OCT)

Up to 27 months
Core Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Lasso di tempo: Up to 27 months

Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG

Up to 27 months
Core Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Lasso di tempo: Up to 27 months

Number of participants with presence/emergence of replication-competent lentivirus

Up to 27 months
Core Phase - Number of participants with malignancy (Cohort 1)
Lasso di tempo: Up to 27 months

Number of participants with malignancy

Up to 27 months
Core Phase - Time to hematological reconstitution (Cohort 1)
Lasso di tempo: Up to 24 months

Time to hematological reconstitution

Up to 24 months
Core Phase - Time to platelet engraftment (Cohort 1)
Lasso di tempo: Up to 24 months

Time to platelet engraftment

Up to 24 months
Core Phase - Incidence of Adverse Events (Cohort 0)
Lasso di tempo: up to 24 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

up to 24 months
Extension Phase Primary Objective - Incidence of Adverse events (Cohort 1)
Lasso di tempo: Up to 15 years and 8 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

Up to 15 years and 8 months
Extension Phase - Number of participants with malignancy (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months

Number of participants with malignancy

Up to 15 years and 3 months
Extension Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months

Number of participants with presence/emergence of replication-competent lentivirus

Up to 15 years and 3 months
Extension Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months

Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR) (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months

Change from baseline on urine protein to creatinine ratio (UPr/CR)

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine amino acids (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months

Change from baseline on urine amino acids

Up to 15 years and 3 months
Extension Phase - Change from baseline on urinary glucose to creatinine ratio (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months

Change from baseline on urinary glucose to creatinine ratio

Up to 15 years and 3 months
Extension Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR) (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months

Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr) (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months

Change from baseline on urine retinol-binding protein/creatinine ratio

Up to 15 years and 3 months
Extension Phase - Duration of reversal of RFS (Cohort 1)
Lasso di tempo: Up to 15 years

Duration of reversal of renal Fanconi syndrome (RFS)

Up to 15 years
Extension Phase - Number of participants with kidney failure (Cohort 1)
Lasso di tempo: Up to 15 years

Number of participants with kidney failure

Up to 15 years
Extension Phase - Number of participants independent from cysteamine (Cohort 1)
Lasso di tempo: Up to 15 years

Independence from oral and ophthalmic cysteamine

Up to 15 years
Extension Phase - Corneal cystine crystal content (Cohort 1)
Lasso di tempo: Up to 15 years and 3 months

Corneal crystal content by anterior segment optical coherence tomography (AS-OCT)

Up to 15 years and 3 months
Extension Phase - Health-related quality of life (HRQOL) (Cohort 1)
Lasso di tempo: Up to 15 years and 8 months

Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development

Up to 15 years and 8 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

2 giugno 2025

Completamento primario (Stimato)

28 maggio 2031

Completamento dello studio (Stimato)

28 maggio 2044

Date di iscrizione allo studio

Primo inviato

17 marzo 2025

Primo inviato che soddisfa i criteri di controllo qualità

27 marzo 2025

Primo Inserito (Effettivo)

4 aprile 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CDFT383A12101

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .